Market Cap 158.08M
Revenue (ttm) 0.00
Net Income (ttm) -129.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 120,300
Avg Vol 110,558
Day's Range N/A - N/A
Shares Out 16.54M
Stochastic %K 99%
Beta -0.11
Analysts Sell
Price Target $30.00

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-489-9000
Address:
561 Eccles Avenue, South San Francisco, United States
StockScanners
StockScanners Jun. 27 at 1:10 AM
$RAPT Reached 9.75, keep watch
0 · Reply
Zipcash
Zipcash Jun. 26 at 11:28 PM
$RAPT breaking $15.00 next week
0 · Reply
BayAreaBiotech
BayAreaBiotech Jun. 26 at 8:06 PM
$RAPT Do you guys think we will get some news regarding the next-gen CCR4 antagonist by tomorrow or Monday, if the company stays true to their words to release CCR4 next-gen updates in the first half of 2025?
3 · Reply
Breqqswings
Breqqswings Jun. 26 at 7:38 PM
$RAPT getting 🥵
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 1:17 PM
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 10:34 AM
$RAPT zero???
0 · Reply
StockScanners
StockScanners Jun. 26 at 12:36 AM
$RAPT Keep watch if this holds above 8.75
0 · Reply
SteveStachion
SteveStachion Jun. 25 at 11:16 PM
$RAPT think this will be a daily climber
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 7:31 PM
$RAPT following closely 👀👀
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 25 at 7:15 PM
$RAPT flying AH?
0 · Reply
Latest News on RAPT
RAPT Therapeutics Announces $150 Million Private Placement

Dec 23, 2024, 7:10 AM EST - 6 months ago

RAPT Therapeutics Announces $150 Million Private Placement


RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus


FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials


RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Aug 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results


RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 13, 2023, 3:59 PM EDT - 2 years ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off


RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results


RAPT Therapeutics: Potential Strong Upside Ahead

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead


RAPT Therapeutics Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2022 Financial Results


StockScanners
StockScanners Jun. 27 at 1:10 AM
$RAPT Reached 9.75, keep watch
0 · Reply
Zipcash
Zipcash Jun. 26 at 11:28 PM
$RAPT breaking $15.00 next week
0 · Reply
BayAreaBiotech
BayAreaBiotech Jun. 26 at 8:06 PM
$RAPT Do you guys think we will get some news regarding the next-gen CCR4 antagonist by tomorrow or Monday, if the company stays true to their words to release CCR4 next-gen updates in the first half of 2025?
3 · Reply
Breqqswings
Breqqswings Jun. 26 at 7:38 PM
$RAPT getting 🥵
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 1:17 PM
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 26 at 10:34 AM
$RAPT zero???
0 · Reply
StockScanners
StockScanners Jun. 26 at 12:36 AM
$RAPT Keep watch if this holds above 8.75
0 · Reply
SteveStachion
SteveStachion Jun. 25 at 11:16 PM
$RAPT think this will be a daily climber
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 7:31 PM
$RAPT following closely 👀👀
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 25 at 7:15 PM
$RAPT flying AH?
0 · Reply
topstockalerts
topstockalerts Jun. 25 at 6:54 PM
$RAPT can’t say you weren’t warned.. 🚨🚨..
0 · Reply
Ianwalsh15
Ianwalsh15 Jun. 25 at 6:35 PM
$RAPT did this reverse split? Sorry haven’t been paying attention
1 · Reply
Breqqswings
Breqqswings Jun. 25 at 6:35 PM
0 · Reply
SteveStachion
SteveStachion Jun. 25 at 6:25 PM
$RAPT 99.42 %held by tutes...thats beyond interesting.. short shares available going up and a low ctb..seems there r mixed reviews on high tute ownership, could be short sales already on lend..does not seem extraordinary tho atm.. could this be lending itself to something else going on with the company? Lots of changes recently, an legit input appreciated. Change on board with veterans, could this be a merger of sorts ahead for the company?? https://www.stocktitan.net/news/RAPT/rapt-therapeutics-names-two-industry-veterans-to-its-board-of-2rfnh17zc71w.html
0 · Reply
Zipcash
Zipcash Jun. 25 at 6:10 PM
$RAPT $20.00 is coming up next . Added and holding for mega gains.
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 25 at 5:58 PM
$RAPT Discover why RAPT Therapeutics could be the next biotech breakout, fueled by promising anti-IgE data, and strong cash reserves. https://biotechhealthx.com/biotech-news/rapt-therapeutics-rapt-poised-for-massive-breakout-after-reverse-split-and-clinical-wins/
0 · Reply
LordsofKarma7
LordsofKarma7 Jun. 25 at 5:41 PM
$RAPT squeezing…???
0 · Reply
Skywalker86
Skywalker86 Jun. 25 at 5:32 PM
$NKTR 👉 $RAPT tying to be sneaky. Sympathy play to $NKTR 🤔
0 · Reply
Breqqswings
Breqqswings Jun. 25 at 5:28 PM
0 · Reply
Breqqswings
Breqqswings Jun. 25 at 3:22 PM
$RAPT after seeing $NKTR and with RAPT having a 97% short I’m pushing all my chips in on this one.
0 · Reply
BayAreaBiotech
BayAreaBiotech Jun. 24 at 8:08 PM
$RAPT RAPT is expected to announce the pivot to next-gen CCR4 antagonist compound soon. They aimed to develop CCR4 antagonists with improved safety profiles and to nominate a new candidate by the first half of 2025, which is literally end of this week. Clear preclinical toxicology data demonstrating a safe margin for liver function would directly address zelnecirnon’s past liver toxicity. If released, this would build confidence in the next-generation molecule and propel the stock price upward. The price movement was decent today. Let’s see what transpires this week.
2 · Reply
stockanalysis_
stockanalysis_ Jun. 21 at 6:20 PM
Most Shorted Stocks: $ALZN $RAPT $NKTR $TSAT $VLDR View the entire list here: https://stockanalysis.com/list/most-shorted-stocks/?ref=saveontrading
0 · Reply